Cohen Yoram, Singer Gad, Lavie Ofer, Dong Seung Myung, Beller Uziel, Sidransky David
Department of Otolaryngology-Head and Neck Surgery, The Johns Hopkins University, Baltimore, Maryland 21205, USA.
Clin Cancer Res. 2003 Aug 1;9(8):2981-4.
Development of adenocarcinoma (AC) of the uterine cervix, as well as squamous cell carcinoma (SCC), is strongly linked to infection by high-risk human papillomavirus (HPV) types. Human HPV E6 and E7 proteins inactivate the tumor suppressor genes p53 and retinoblastoma, respectively. However, additional genetic alterations may be required to maintain a malignant phenotype. Allelic loss at the short arm of chromosome 3 is one of the most frequent genetic changes found in cervical cancer and various other types of human cancer, including lung, breast, and ovarian cancer. This implies that a resident tumor-suppressor gene in this region is involved in the genesis of these tumors. RASSF1A, which is located at 3p21.3, is rarely inactivated by mutations but has been suggested as a target tumor suppressor gene on the basis of its frequent inactivation through promoter hypermethylation and loss of heterozygosity in a variety of primary human cancers. In the present study, we sought to determine whether epigenetic silencing of RASSF1A caused by hypermethylation of the promoter region plays a role in the development of uterine cervical cancer.
We studied 51 uterine cervical carcinoma samples. These 51 cases were comprised of 31 SCCs and 20 ACs. Real-time methylation-specific PCR system was used for the detection and quantitation of the bisulfite-converted methylated version of the RASSF1A promoter region. The 20 cases of cervical AC were also analyzed for the presence of oncogenic HPV 16 DNA using a PCR-based method.
We found complete methylation of the RASSF1A promoter in 45% (9 of 20 samples) of AC cases. There was no promoter methylation observed in any of the 31 cases of SCC. We also correlated RASSF1A promoter hypermethylation to oncogenic HPV 16 infection. HPV 16 DNA was found in 3 of 9 (33%) AC tumors with RASSF1A promoter hypermethylation and 5 of 11 (45%) AC tumors without RASSF1A promoter hypermethylation. We could not demonstrate an inverse correlation between RASSF1A methylation and HPV 16 infection in AC of the uterine cervix.
Hypermethylation of the RASSF1A promoter region is common in AC of the uterine cervix and rare in squamous carcinoma of uterine cervix. HPV infection does not correlate with RASSF1A methylation status in AC of the uterine cervix, but the absence of RASSF1A methylation in SCC of the uterine cervix coupled with the high incidence of HPV 16 infection in this subtype is in accord with previous reports. Our results suggest that epigenetic silencing of RASSF1A may play a role in the development of AC of the uterine cervix.
子宫颈腺癌(AC)以及鳞状细胞癌(SCC)的发生与高危型人乳头瘤病毒(HPV)感染密切相关。人HPV E6和E7蛋白分别使肿瘤抑制基因p53和成视网膜细胞瘤失活。然而,可能需要其他基因改变来维持恶性表型。3号染色体短臂的等位基因缺失是在宫颈癌以及包括肺癌、乳腺癌和卵巢癌在内的其他多种人类癌症中发现的最常见的基因变化之一。这表明该区域存在的一个肿瘤抑制基因参与了这些肿瘤的发生。位于3p21.3的RASSF1A很少因突变而失活,但基于其在多种原发性人类癌症中因启动子高甲基化和杂合性缺失而频繁失活,已被认为是一个靶肿瘤抑制基因。在本研究中,我们试图确定由启动子区域高甲基化引起的RASSF1A表观遗传沉默是否在子宫颈癌的发生中起作用。
我们研究了51例子宫颈癌样本。这51例包括31例SCC和20例AC。使用实时甲基化特异性PCR系统检测和定量经亚硫酸氢盐转化的RASSF1A启动子区域的甲基化形式。还使用基于PCR的方法分析了20例子宫颈AC样本中致癌性HPV 16 DNA的存在情况。
我们发现20例AC样本中有45%(9/20)的RASSF1A启动子完全甲基化。31例SCC样本中均未观察到启动子甲基化。我们还将RASSF1A启动子高甲基化与致癌性HPV 16感染相关联。在9例RASSF1A启动子高甲基化的AC肿瘤中有3例(33%)检测到HPV 16 DNA,在11例无RASSF1A启动子高甲基化的AC肿瘤中有5例(45%)检测到HPV 16 DNA。我们未能证明子宫颈AC中RASSF1A甲基化与HPV 16感染之间存在负相关。
RASSF1A启动子区域高甲基化在子宫颈AC中常见,而在子宫颈鳞状细胞癌中罕见。HPV感染与子宫颈AC中RASSF1A甲基化状态无关,但子宫颈SCC中无RASSF1A甲基化以及该亚型中HPV 16感染的高发生率与先前报道一致。我们的结果表明,RASSF1A的表观遗传沉默可能在子宫颈AC的发生中起作用。